Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been given a consensus rating of “Buy” by the eight analysts that are presently covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $59.20.

A number of research firms recently commented on ARCT. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Wells Fargo & Company cut their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Canaccord Genuity Group dropped their price target on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday. Finally, HC Wainwright cut their price objective on Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, March 7th.

Institutional Trading of Arcturus Therapeutics

Hedge funds have recently modified their holdings of the stock. Los Angeles Capital Management LLC acquired a new position in Arcturus Therapeutics in the third quarter valued at approximately $544,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after purchasing an additional 712,650 shares during the period. Royce & Associates LP boosted its holdings in Arcturus Therapeutics by 18.3% during the third quarter. Royce & Associates LP now owns 155,803 shares of the biotechnology company’s stock worth $3,616,000 after buying an additional 24,085 shares in the last quarter. Quest Partners LLC grew its position in Arcturus Therapeutics by 437.1% during the third quarter. Quest Partners LLC now owns 19,810 shares of the biotechnology company’s stock valued at $460,000 after buying an additional 16,122 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its position in Arcturus Therapeutics by 28.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 48,957 shares of the biotechnology company’s stock valued at $1,136,000 after buying an additional 10,728 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Trading Up 7.9 %

Shares of ARCT opened at $14.26 on Monday. The firm has a market cap of $386.73 million, a PE ratio of -6.42 and a beta of 2.96. Arcturus Therapeutics has a 12 month low of $12.75 and a 12 month high of $45.00. The stock has a fifty day moving average price of $16.78 and a 200-day moving average price of $18.41.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The business had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. As a group, research analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.